Sanofi's new CEO, Belén Garijo, is reconsidering the company’s research priorities following lackluster results in immunology. This shift could signal a significant reallocation of resources and focus for Sanofi, impacting developers and tech professionals working on current projects. Watch for potential investments in emerging areas like gene therapy or digital health solutions to drive future growth.
Read the full article at STAT Pharma
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.





